Background. Omega-3 fatty acids supplements lower triglyceride (TG) levels in adults; little pediatric information is available. We evaluated their effect in hypertriglyceridemic adolescents. Methods. Twenty-five patients aged 10 to 19 years with TG levels 150 to 1000 mg/dL were randomized to 6 months double-blind trial of Lovaza (~3360 mg docosahexaenoic acid + eicosapentaenoic acid per day) versus placebo. Results. Baseline mean TG levels were 227 mg/dL (standard deviation = 49). TG levels declined at 3 months in the Lovaza group by 54 ± 27 mg/dL (mean ± standard error; P = .02) and by 34 ± 26 mg/dL (P = .16) in the placebo group. The difference in TG lowering between groups was not significant (P = .52). There were no between-group differences in endothelial function, blood pressure, body mass index, C-reactive protein, or side effects. Conclusions. High-dose omega-3 fatty acid supplements are well tolerated in adolescents. However, declines in TG levels did not differ significantly from Placebo in this small study.
Introduction
Elevated triglyceride (TG) levels have been shown to be an independent risk factor for coronary heart disease in some studies, 1, 2 and severe TG elevations increase the risk for acute pancreatitis. 3 Lifestyle modification is the primary therapy, but compliance is generally poor. Cardiovascular benefits have been described from dietary and supplemental omega-3 fatty acids (FAs), in particular the marine-derived FAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), [4] [5] [6] [7] with diet and higher dose omega-3 FA supplements having more benefit. 8, 9 The strongest and most consistent cardiometabolic effect of EPA and DHA supplements has been the TG-lowering effect, [5] [6] [7] which can produce declines in plasma TG levels of 25% to 30% when given in doses of 3 to 4 g/d. 6 Despite these important declines in TG levels, controversy exists about their role in clinical care, related to the questionable benefits of low dose (1 g/d) supplements. 10, 11 Hypertriglyceridemia is relatively common among youth, affecting 12% of teens, 12 and is often related to obesity. 13 Pharmacotherapy, including fibrates and niacin is used in adults, but the effect on cardiovascular disease (CVD) events is debated. 14, 15 The few studies of fibrates in children have shown them to be reasonably safe and effective in lowering TG levels, but are of short duration, small size and in special populations. [16] [17] [18] One published report of pediatric patients treated with niacin demonstrated high rates of drug discontinuation related to difficulties with flushing, headaches and rash. 19 The role of omega-3 FA supplementation in treating pediatric lipid disorders is less explored. Previous trials in children and adolescents have tested low doses of omega-3 FA supplements and have shown variable results. Engler et al 20 tested low-dose (1.2 g/d DHA) for 6 weeks and found no statistically significant lowering of TG levels in patients with familial hypercholesterolemia or familial combined hypercholesterolemia; however, these children had only mildly elevated TG levels (133 ± 68 mg/dL). Other trials also used lower doses of supplements and found either no effect 21 or minimal effect at low dose. 22 This study evaluates the efficacy and safety of omega-3 FA supplements (Lovaza) in youth with moderate to severe hypertriglyceridemia. We also explored biologic mechanisms and therapeutic potential for CVD risk factors, including blood pressure, insulin resistance, vascular function, and inflammation.
Methods

Study Design and Population
We conducted a double-blind placebo controlled randomized trial to evaluate the efficacy and safety of omega-3 FA in reducing TG levels in healthy youth aged 10 to 19 years with moderate to severe hypertriglyceridemia. Patients were recruited from subspecialty and primary care clinics at Boston Children's Hospital and from referrals from community pediatricians. They were eligible to participate if they had a fasting TG level that was 150 to 1000 mg/dL and met all other study inclusion and exclusion criteria. Inclusion criteria included the ability to swallow pills and speak English. Patients were excluded if they reported allergy to fish, corn, or other components of the pills, pregnancy or breast-feeding, alcohol use, bleeding disorder or coagulopathy, thyroid disorder, diabetes or fasting glucose at or above 126 mg/ dL, liver disease or alanine aminotransferase (ALT) greater than 2 times the upper limit of normal, treatment with medications affecting TG levels, including oral hypoglycemic agents, insulin, nonstatin lipid-lowering medications, or omega-3 FA pills.
Eligible subjects who provided informed consent participated in a 1-month dietary counseling run-in period. Only those subjects whose TG levels remained 150 to 1000 mg/dL at the baseline visit were randomized to either four 1-g capsules daily of Lovaza or placebo for 6 months. Randomization was conducted and assigned by the research pharmacy of Boston Children's Hospital using a list generated by the Clinical Research Center. Randomization was blocked to yield roughly equivalent group assignment over time. Study staff and subjects were blinded to treatment assignment. Follow-up measurements were conducted at 3 and 6 months after randomization. The primary outcome was defined as change in TG levels from baseline at 3 months. Secondary outcomes included TG levels at 6 months, blood pressure, total cholesterol (TC), very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol at 3 and 6 months. Exploratory outcomes included C-reactive protein (CRP), homeostasis model of assessment-insulin resistance (HOMA-IR) as a measure of insulin resistance, and endothelial function measured by pulse amplitude testing (EndoPAT, Itamar Medical, Franklin, MA). Adult subjects and parents gave written informed consent; all minor subjects gave assent. Subjects received a heart-healthy snack postfast, parking reimbursement, and a gift card on completing each study visit. The study protocol was approved by the institutional review board of Boston Children's Hospital.
Intervention
Lovaza (GlaxoSmithKline, Research Triangle Park, NC) is a purified preparation of omega-3 long-chain polyunsaturated FA. Each 1-g capsule contains a total of 840 mg of omega-3 FA, 465 mg as EPA and 375 mg as DHA, in 4 mg of carrier vegetable oil. Each placebo capsule contained 1 g of corn oil as well as <0.05% of trans-FA. Both Lovaza and placebo capsules contained a small amount of iron oxide, used for color blinding, and tocopherol to prevent oxidation.
In addition to the study drug, all participants were advised by a registered dietician to follow a diet low in refined carbohydrate and saturated fat that emphasized increasing intake of fruits and vegetables and consumption of 2 servings per week of fish rich in omega-3 FA. This is standard of care at our institution and is consistent with National Heart, Lung and Blood Institute Integrated Guidelines for Cardiovascular Risk Reduction in Children and Adolescents. 23 
Measurements
All study visits were conducted in the Boston Children's Hospital Clinical and Translational Research Center by trained staff. Anthropometrics were measured in triplicate while wearing light clothing and no shoes using a stadiometer and digital scale. Waist circumference was measured at the superior-inferior iliac crest using a metal measuring tape. Blood pressure was auscultated 3 times, 1 minute apart in a quiet room after a 5-minute rest period in the right arm using an appropriate sized cuff. Measurements were averaged for the analysis. All patients had a physical exam at the screening visit, and completed self-administered questionnaires with the help of their parent(s) on medical and family history, frequency of fish intake, lifestyle behaviors, and the occurrence of potential side effects (eg, baseline muscle and gastrointestinal complaints). A 24-hour dietary recall was conducted at each study visit; the results were analyzed using Nutrition Data Services 24 and standard dietary characteristics were calculated, including macronutrients, omega-3 FA intake, and glycemic load (GL), which was calculated as the product of the foods' glycemic index, using a white bread standard, and the amount of carbohydrate divided by 100. 25 Lifestyle behaviors, potential side effects, dietary intake by 24-hour recall and fish intake specifically were re-assessed at each study visit.
Laboratory Tests
Blood samples were obtained after a 12-hour fast. Subjects were instructed to reschedule their visit if they had a febrile illness, because of the effect of acute illness on TG levels. TC, TG, and HDL cholesterol were measured using standard methods. LDL cholesterol was calculated using the Friedewald calculation 26 or measured directly in patients with TG levels >400 mg/dL using the homogenous method (Genzyme Corporation, Cambridge, MA). VLDL cholesterol levels were calculated by dividing the TG level by 5. Insulin resistance was estimated using HOMA-IR, which is highly correlated with the euglycemic-hyperinsulinemic clamp in obese and nonobese children and adolescents. 27 HOMA was calculated as follows: fasting plasma insulin (µU/ mL) × fasting plasma glucose (mmol/L)/22.5. Highsensitivity CRP was measured by an immunoturbidimetric assay on the Hitachi 911 analyzer (Roche Diagnostics, Indianapolis, IN).
Vascular Testing
Trained study staff assessed vascular function non-invasively using EndoPAT (Itamar Medical) after a 12-hour fast. EndoPAT is a Food and Drug Administrationapproved method of noninvasively assessing endothelial function and has been shown to be reliable in healthy adolescents. 28 Postocclusive volume changes at the fingertip are compared between the occluded and nonoccluded arm. EndoPAT has been correlated with brachial artery reactivity testing and validated against coronary artery endothelial dysfunction in adults. 29, 30 
Measures of Compliance
Participants were asked to return their leftover pills and bottles. Red blood cell (RBC) membrane levels of EPA and DHA were measured to assess compliance as well as exposure to and absorption of dietary sources of DHA and EPA. FAs were identified by comparison with a custommade, weighed, standard mixture consisting of 19 FAs characteristic of RBC (GLC-673b, Nuchek Prep, Elysian, MN). Coefficients of variation (CVs) were reported from the manufacturer as being derived from more than 200 runs across 4 instruments. At a low HS-Omega-3 Index (1.7%), the CV of this testing is 6.8%, and at a high HS-Omega-3 Index (11.0%), the CV is 2.5%.
Statistical Methods
The study was designed with 80% power to detect a 20% net decrease in TG levels in the omega-3 FA group when compared with TG level changes in the placebo group from a sample size of 60 patients. Patients' characteristics and baseline measures were compared between treatment arms by Student's t test for continuous measures or Fisher's exact test for discrete traits. The time course of each outcome variable, from baseline to 3 months to 6 months, was compared between treatment arms by repeated-measures analysis of variance, using an autoregressive covariance structure. From parameters of the fitted model, we constructed estimates for the mean value at each time point; the mean change at 3 months and 6 months; the difference between arms in mean change at 3 months and 6 months; and standard errors for all of the above, permitting the changes and differences to be compared to zero by Student's t test. In cases of skewed distribution, we analyzed the log-transformed variable and retransformed the means and changes for reporting net changes. In cases of extreme skew, we used nonparametric summary statistics and tests, namely, median and range; signed-rank test for zero median change; and Wilcoxon rank-sum test for difference in distribution of changes between treatment arms. The association between TG levels and DHA + EPA levels was assessed using Pearson correlation coefficient. A 2-sided P < .05 was the criterion for statistical significance. Statistical Analysis System software (version 9.2, SAS Institute, Cary, NC) was employed for all computations. The primary analyses were performed with the intention to treat principle.
Results
Participants
The medical records of 622 patients, aged 10 to 19 years with TG levels 150 to 1000 mg/dL were reviewed for eligibility between July 2008 and October 2011, and 331 met initial the eligibility criteria for screening. Ultimately 25 participants were randomized for participation ( Figure 1 ). One patient dropped out after randomization before the 3-month visit, and 3 patients dropped out after the 3-month visit; all 4 had been randomized to the placebo group. All randomized participants were recruited from Boston Children's Hospital subspecialty clinics, either Preventive Cardiology (n = 21) or Optimal Weight for Life (n = 3). The study was stopped early because of the low recruitment rate.
Patient characteristics were comparable between the 2 groups at baseline ( group. None of the randomized participants took a statin or oral contraceptive pill at any point during the study.
Lipid Outcomes
Triglyceride levels declined significantly in the omega-3 FA group at 3 months and 6 months after baseline (−54 ± 27 mg/dL; P = .02 and −61 ± 31 mg/dL; P = .03, respectively); Figure 2 , panel A and Table 2 . TG levels also declined in the placebo group at each time point (−34 ± 26 mg/dL; P = .16 and −31 ± 33 mg/dL; P = .32, respectively); however, this decline did not reach statistical significance. When the change in TG level was examined, there was no statistically significant difference between the 2 groups at either time point. Compliance with study medication was assessed by RBC membrane EPA and DHA levels and by pill counts. Figure 2 , panel B shows RBC EPA + DHA levels and TG levels in the study groups over time. EPA + DHA levels were low at baseline in both groups (median 4%) and increased significantly in the omega-3 FA group over the course of the study (1.9-fold at 3 months and 6 months; P < .0001) but did not change in the placebo group. When the relationship between TG levels and EPA + DHA was evaluated in the omega-3 FA group, TG levels were significantly and inversely related to DHA + EPA levels (r = −0.46, P = .02). There were no differences in levels by age or sex. Pill counts suggested good compliance at about 80% in both groups. Table 2 shows changes in lipid parameters over time. LDL levels increased significantly in the omega-3 FA group by 14 ± 6 mg/dL (P = .02) at 3 months but not at 6 months (7 ± 8 mg/dL; P = .37) and were unchanged in the placebo group at both time points. Again, when the change from baseline to 3 months or 6 months was compared between groups, there was no significant difference in LDL change. VLDL cholesterol decreased significantly in the treatment group at 6 months (P = .04). No significant changes were seen in any of the other lipid parameters within or between groups at any other time points.
Nonlipid Outcomes and Safety Measures
Changes in nonlipid parameters are shown in Table 3 . Weight increased in both groups at both time points but the difference between groups was not significant. There was also no difference between groups in change in body mass index (BMI), BMI z score, waist circumference, and systolic blood pressure (BP). Diastolic BP decreased more in the placebo group than the omega-3 FA group at 3 months (P = .02) but not at 6 months (P = .25). Fasting glucose, fasting insulin, and HOMA-IR did not change significantly in the omega-3 FA group, and there were no significant differences between groups at either time point. The majority of CRP levels were at the lower limit of reporting (0.1 mg/dL), and the prevalence of detectable CRP showed no change (P = .28) or difference in time course between treatment groups (P = .62) (data not shown). Vascular function by EndoPAT was consistent with values reported in healthy normal weight adolescents 28 and did not change over time (data not shown). Safety labs were normal on average throughout the study, and there was no significant difference between groups over time (data not shown).
Tolerability
Potential adverse and side effects were specifically assessed by questionnaire at each time point, including at baseline. We asked about burping, upset stomach, abdominal gas, bloated feeling, unusual taste, stomach pains/cramps, loose stools, chest pain, back pain, muscle or joint aches, skin rash, fever and chills, and infection. Musculoskeletal and gastrointestinal complaints were commonly reported in all participants at baseline prior to randomization (28% and 80%, respectively) and at all follow-up study time points (36% and 28% for musculoskeletal, 44% and 44% for gastrointestinal at 3 and 6 months, respectively). There were no significant increases in the frequency of reported symptoms within groups or differences between groups at baseline, 3 months and 6 months in reported musculoskeletal, gastrointestinal, infectious or rash (P = .3-1.0). One female participant receiving omega-3 FA who had recently experienced menarche developed prolonged menstrual bleeding; laboratory testing showed no defects in coagulation (including a normal bleeding time), and her symptoms were thought by study physicians and her primary care provider to be unrelated to the study drug. Safety laboratory tests, including transaminases, blood urea nitrogen, creatinine, platelets, prothrombin, and partial thromboplastin time were normal and did not differ between groups (data not shown).
Nutrition and Physical Activity
There were no consistent changes in dietary intake over time (data not shown). Although statistical significance was not met, the placebo group showed a trend toward a decline in glycemic load, percentage of total calories from carbohydrate, and added sugars. Those in the placebo group also had a nonsignificant increase in fish intake and in dietary intake of omega-3 FA. Reported physical activity was similar in the omega-3 FA and placebo groups (data not shown).
Discussion
In this randomized double blind placebo controlled trial of high-dose omega-3 FA supplements TG levels declined in both the omega-3 FA and the placebo group (24% vs 16% at 3 months, sustained at 6 months), although the difference in the decline between the groups did not reach statistical significance. We demonstrated good safety and tolerability of omega-3 FA, despite reports of gastrointestinal side effects in patients taking high doses of fish oil. 8 Studies of omega-3 FA supplements in adults show a dose-dependent TG lowering effect in healthy volunteers, patients with CVD, and patients with dyslipidemia. [5] [6] [7] A review of 65 well-controlled clinical trials using 3 to 4 g/d of combined EPA and DHA doses of 4 g/d produced a 25% to 30% reduction in TG levels, with stronger TG lowering effect seen among patients with higher baseline TG. 7 In patients receiving omega-3 FA, LDL cholesterol increased 5% to 10% and HDL cholesterol increased 1% to 3%. 6 Although our results did not meet statistical significance, changes in lipid parameters were similar to those reported in adults.
Very few studies have examined the use of omega-3 FA supplements to treat elevated TG in children. Engler et al 20 conducted a randomized placebo controlled crossover trial of diet and DHA supplementation (1.2 g/d, 6 capsules of oil per day) in 20 children with familial hypercholesterolemia or familial combined hyperlipidemia. They showed an 11% decrease in fasting TGs from 133 to 119 mg/dL in the treated group and essentially no change in the placebo group; the findings were not statistically significant. In that study, baseline TG levels were only mildly elevated, (mean ± standard deviation = 139 ± 82 mg/dL), and baseline LDL was extremely high (275 ± 89 mg /dL), suggesting many of these patients might have met criteria for statin therapy. Several other small trials have tested the effect of omega-3FA in pediatric patients with hypertriglyceridemia, but used lower doses and found either no, 21 or minimal (−14 mg/dL) triglyceride lowering effect at low doses. 22 Docosahexaenoic acid and EPA supplements have been shown to be generally safe in adults; 4, 31 our trial also demonstrates safety in children and adolescents. Worsening glycemic control has been reported in diabetic patients, 31 although other reports suggest omega-3 FA may improve glucose homeostasis. 32, 33 None of our participants had diabetes, but many had insulin resistance and we observed no change in HOMA-IR or fasting insulin levels within or between groups.
The underlying mechanism by which omega-3 FA affects lipids is not fully understood. Omega-3 FAs may lower plasma TGs by decreasing hepatic secretion of VLDL cholesterol and by increasing chylomicron metabolism. 34 Increased intake reduces the synthesis of VLDL by inhibiting enzymes in TG synthesis. 35 Omega-3 FAs may have other beneficial effects, including inhibiting adverse inflammatory responses, decreasing platelet aggregation, preventing thrombosis and cardiac arrhythmias, and decreasing cholesterol accumulation in the arterial wall. 36, 37 Omega-3 FAs may directly improve endothelial vasomotor function, including brachial artery reactivity 38, 39 and vascular biomarkers. [40] [41] [42] We did not demonstrate any improvements in vascular reactivity, which could be related to low statistical power or a lack of effect of omega-3 FAs on vasculature.
Strengths of our study include randomization and blinding, low dropout rates, rigorous data collection, and the assessment of a range of relevant physiologic variables. Weaknesses of the study include diminished power due to low enrollment rates, despite the fact that we used many different recruitment strategies. Recruitment was likely difficult in part because our patient population did not feel ill, did not perceive any acute risk to hypertriglyceridemia, and could obtain omega-3FA supplements over the counter. The attained sample size was 24, and the observed net decline in mean TG was 20 mg/dL, or 10% of baseline levels. Post hoc power calculations indicate that to demonstrate statistical significance for an effect of that magnitude, the present study carried less than 10% power. More than 200 participants would be needed for each group in order to have 80% power to show a significant TG-lowering effect by omega-3 FA, if indeed there is an effect of the observed magnitude. Our results also may have been diluted by differential changes in diet, since patients in the placebo group tended to report more favorable changes in glycemic load and added sugar, and increased ingestion of fish/dietary omega-3 FA. It is notable that our patients responded nicely to our nutritional counseling; TG levels declined 28 mg/dL between screening and baseline visits and 11 patients were excluded from the trial because their TG levels normalized. TG declined a further −34 ± 26 mg/dL over 3 months in the placebo group, demonstrating the continued benefit of lifestyle counseling in pediatric hypertriglyceridemia.
Conclusion
The treatment of hypertriglyceridemia during childhood relies primarily on dietary modification. For those children who are unable to adequately implement lifestyle modification, or for whom lifestyle modification is insufficient to achieve substantial TG lowering, few pharmacologic options exist and data on their use during childhood are sparse. Omega-3 FA supplements may represent a tolerable and safe option for these children. Because preclinical atherosclerotic vascular disease is found in youth, CVD risk factor levels track into adulthood and predict adult vascular changes, 23, [43] [44] [45] childhood may be a critical period during which omega-3 FAs can have important health benefits.
